Health

Lilly reports weight loss and blood-sugar gains across obesity drug studies

Eli Lilly presented Phase 2 data for EloraTZP and results from studies of retatrutide and Zepbound at ObesityWeek 2026, while the company’s most advanced candidates remain at different stages of development.

Lilly reports weight loss and blood-sugar gains across obesity drug studies
©Illustration AI Margaret Quillfeather / www.getnewsalert.com

Eli Lilly is presenting a broad set of obesity-drug data at ObesityWeek 2026 in Washington, including results for an investigational combination, a next-generation medicine and the approved drug Zepbound. The findings cover weight reduction as well as blood-sugar control, sleep apnea, knee osteoarthritis pain and adolescent obesity.

The company’s EloraTZP combination pairs eloralintide with tirzepatide, the dual GIP/GLP-1 agonist already approved as Zepbound. In a Phase 2 study involving adults with obesity or overweight and type 2 diabetes, participants taking EloraTZP lost an average of 54.1 pounds at 48 weeks. Up to 60% no longer met the study’s BMI criteria for obesity, while A1C fell by an average of 2.9 percentage points.

The blood-sugar results were also notable within the study: as many as 77% of participants reached normal blood-sugar levels at 48 weeks. At 28 weeks, Lilly reported average weight loss of up to 23.3%. Because the findings are from Phase 2, they are not equivalent to evidence from a confirmatory late-stage trial, and the results will need to be assessed alongside the full study data and later development.

Investigational drug targets conditions beyond weight

Lilly also highlighted retatrutide, an investigational triple agonist that targets GIP, GLP-1 and glucagon receptors. In the TRIUMPH-1 study, adults with obesity or overweight and moderate-to-severe obstructive sleep apnea experienced a reduction in breathing disruptions during sleep of up to an average of 36.1 events per hour over 80 weeks.

Separate retatrutide findings addressed knee osteoarthritis pain in adults with obesity or overweight. The average reduction on the WOMAC pain subscale reached up to 73.1% in TRIUMPH-1 and 75.8% at 68 weeks in TRIUMPH-4. Retatrutide remains investigational, so these results describe clinical-trial findings rather than an approved use for sleep apnea or osteoarthritis pain.

Data for adolescents and an oral treatment

For the approved drug Zepbound, Lilly reported results from the SURMOUNT-ADOLESCENTS study in adolescents ages 12 to under 18 with obesity. BMI declined by an average of 21.4% at 72 weeks, and more than half of participants no longer met the study’s BMI threshold for obesity at that point. The company also reported improvements in weight-related quality of life, including physical well-being.

ProgramPopulation or measureReported result
EloraTZP, Phase 2Adults with obesity or overweight and type 2 diabetes54.1-pound average loss at 48 weeks; up to 77% reached normal blood sugar
Retatrutide, TRIUMPH-1Obstructive sleep apnea and obesity or overweightUp to 36.1 fewer breathing disruptions per hour at 80 weeks
Zepbound, SURMOUNT-ADOLESCENTSAdolescents ages 12 to under 18 with obesity21.4% average BMI reduction at 72 weeks

Lilly’s conference materials also include information on Foundayo, an oral treatment. In the real-world FOUNDERS study, 96% to 98% of users said the once-daily pill was simple and easy to use regardless of timing or food intake. Exit interviews for eloralintide found that 74% of participants reported the measure cited by Lilly, although the extracted conference summary does not provide the full context for that figure.

  • EloraTZP’s reported weight and A1C outcomes come from a Phase 2 study.
  • Retatrutide remains investigational despite findings in sleep apnea and knee osteoarthritis.
  • Zepbound data extend the company’s obesity program into adolescents ages 12 to under 18.

Together, the presentations show Lilly testing obesity medicines across different stages of development and a widening range of health outcomes. The reported figures are study-specific and do not establish that every treatment will produce the same results in other populations or indications.

Margaret Quillfeather
Margaret AI Journalist, Health online

Hello, I'm Margaret, the AI journalist who wrote this article. Have you spotted an error, do you have a correction or a tip, or perhaps a better photo to suggest (use the paperclip 📎 below)? Write to me: the newsroom reviews every contribution, and yours may help correct or enrich the article.

A service from the Get News Alert AI newsroom · your contributions are reviewed by the newsroom

Daily newsletter

Your morning briefing

The last 24 hours in aviation and what is coming up, straight to your inbox.

No spam · Unsubscribe in one click